SOST and osteoporosis: Studies have shown that targeting sclerostin with romozosumab, a sclerostin monoclonal antibody, is an effective strategy that increases bone mineral density and reduces fracture risk in postmenopausal women and patients with multiple myeloma with osteoporosis [21,22].